GlassScriptPhysician profile
Eric C Kozfkay
NPI 1497710610
$20,179.73
in general payments reported to CMS, 2019-2025
34 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $1,028 · 2021: $1,593 · 2022: $1,253 · 2023: $990 · 2024: $386 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $13,888.06 | 2019-2020 | |
| Vertos Medical, INC. | $2,037.54 | 2019-2024 | Mild Device Kit |
| Boston Scientific Corporation | $1,141.85 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Relievant Medsystems, INC. | $375.37 | 2020-2023 | Intracept |
| Abbott Laboratories | $340.31 | 2019-2025 | Proclaim |
| Nevro Corp. | $266.48 | 2019-2024 | Senza |
| Saluda Medical Americas, INC. | $261.24 | 2025 | Evoke |
| Pfizer INC. | $232.65 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $219.69 | 2020-2024 | Xtampza, Belbuca |
| Teva Pharmaceuticals USA, INC. | $157.74 | 2019-2022 | |
| Abbvie INC. | $156.90 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $126.71 | 2019-2020 | |
| Amgen INC. | $124.88 | 2019-2025 | Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $106.36 | 2022 | |
| Grt US Holding, INC. | $103.03 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $79.88 | 2019 | |
| Stryker Corporation | $76.56 | 2024 | Mild Device Kit |
| Medtronic USA, INC. | $67.91 | 2019 | |
| Allergan, INC. | $52.85 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $48.64 | 2019 | |
| Biodelivery Sciences International, INC. | $44.22 | 2019-2021 | |
| Assertio Therapeutics, INC. | $40.10 | 2019 | |
| Spr Therapeutics, INC | $35.40 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $30.72 | 2021 | |
| Si-Bone, INC. | $23.95 | 2021 | |
| Glaxosmithkline, LLC. | $21.46 | 2025 | Trelegy Ellipta |
| Averitas Pharma INC. | $20.46 | 2023 | Qutenza |
| Lilly USA, LLC | $18.97 | 2025 | Zepbound, Mounjaro |
| Fidia Pharma USA INC. | $18.11 | 2022 | |
| Axonics, INC. | $17.20 | 2021 | |
| Medtronic, INC. | $15.95 | 2021 | |
| Radius Health, INC. | $15.74 | 2022 | |
| Ibsa Pharma INC. | $12.80 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kozfkay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.